<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-285RHLTS</identifier><date>2022</date><creator>Bolčina, Lara</creator><creator>Jovchevska, Ivana</creator><creator>Kump, Ana</creator><creator>Žužek, Zala</creator><relation>documents/doc/2/URN_NBN_SI_doc-285RHLTS_001.pdf</relation><relation>documents/doc/2/URN_NBN_SI_doc-285RHLTS_001.txt</relation><format format_type="issue">1</format><format format_type="volume">73</format><format format_type="type">article</format><format format_type="extent">str. 23-30</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">104195331</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-285RHLTS</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">CAR-T</subject><subject language_type_id="slv">glioblastom</subject><subject language_type_id="eng">glioblastoma</subject><subject language_type_id="slv">imunoterapija</subject><subject language_type_id="eng">metformin</subject><subject language_type_id="eng">valproic</subject><title>Drug repurposing</title><title>metformin and valproic acid for glioblastoma treatment</title><title>metformin in valprojska kislina za zdravljenje glioblastoma</title><title>Repozicioniranje zdravil</title></Record>